Denise M. Wolf

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Developing early endpoints in neoadjuvant breast cancer to support accelerated approval.

  Journal of Clinical Oncology · 2026-05-28

• Predicting treatment effect on distant recurrence free survival from functional tumor volume change during neoadjuvant therapy: A Bayesian hierarchical model of I-SPY 2 MRI and survival data.

  Journal of Clinical Oncology · 2026-05-27

• Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer

  Science Translational Medicine · 2026-04-22

• Abstract 2994: Integrative pathway analysis of I-SPY2 HER2+ breast cancers reveals drug-repurposing opportunities

  Cancer Research · 2026-04-03

• Bayesian adaptive randomization in the I-SPY2 sequential multiple assignment randomized trialPreprint

  Biometrics · 2026-03-28

• Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

  Nature Communications · 2025-12-09 · 6 citations

• Data from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast CancerPreprint

  2025-10-15

• Supplementary Figure 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast CancerPreprint

  2025-10-15

• Supplementary Tables 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer

  2025-10-15

• Validation of an MRI-Based Predictive Model for Treatment Tailoring in the I-SPY 2 Trial

  Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition · 2025-09-16

• Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-08-28

• Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer

  Clinical Cancer Research · 2025-08-11 · 3 citations

• Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial

  JCO Precision Oncology · 2025-06-01 · 5 citations

• Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.

  Journal of Clinical Oncology · 2025-05-28

• Association of ImPrintTN signature with survival outcomes by race in basal-type triple negative breast cancer (TNBC): FLEX registry analysis.

  Journal of Clinical Oncology · 2025-05-28

• Gene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts.

  Journal of Clinical Oncology · 2025-05-28

• Abstract B042: Differential prevalence of immune-associated germline variants across genetic ancestry groups may partially underlie racial and ethnic disparities in breast cancer outcomes

  Cancer Research · 2025-03-11

• MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer

  Tomography · 2025-02-27 · 4 citations

• Supplementary Tables 1 from Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers

  2025-01-17

• Supplementary Figure 1 from Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast CancersPreprint

  2025-01-17